论文部分内容阅读
目的探讨贝那普利和吲达帕胺小剂量联合治疗轻、中度原发性高血压的疗效及安全性。方法将本院2009年2月-2010年12月收治的120例原发性高血压患者随机分为对照组(55例)和治疗组(65例),对照组口服贝那普利10 mg/次.d,治疗组口服贝那普利5 mg/次.d+吲达帕胺1.25 mg/次.d。给药8周后,观察患者血压、心率、生化指标及不良反应。结果用药8周后,两组患者收缩压(SBP)、舒张压(DBP)均显著下降(P<0.05);治疗组和对照组总有效率分别为95.4%和72.7%,两组比较差异有统计学意义(P<0.05);治疗组和对照组不良反应发生率分别为13.8%和25.5%,差异有统计学意义(P<0.05),但均能耐受;两组治疗前后心率及生化指标差异无统计学意义(P>0.05)。结论较单用贝那普利相比,贝那普利联合吲达帕胺降压效果显著提高;对心率、血糖、总胆固醇等生化指标等无显著影响;且不良反应发生率低,安全可靠。
Objective To investigate the efficacy and safety of combination of benazepril and indapamide in the treatment of mild to moderate essential hypertension. Methods A total of 120 patients with essential hypertension admitted from February 2009 to December 2010 in our hospital were randomly divided into control group (55 cases) and treatment group (65 cases). The control group received benazepril 10 mg / Times .d, the treatment group oral benazepril 5 mg / time.D + indapamide 1.25 mg / time.d. After 8 weeks of administration, the patients’ blood pressure, heart rate, biochemical indexes and adverse reactions were observed. Results After 8 weeks of treatment, systolic blood pressure (SBP) and diastolic blood pressure (DBP) decreased significantly in both groups (P <0.05). The total effective rates in the two groups were 95.4% and 72.7%, respectively (P <0.05). The incidences of adverse reactions in the treatment group and control group were 13.8% and 25.5%, respectively, with statistical significance (P <0.05), but both were able to tolerate the heart rate and biochemistry No significant difference in indicators (P> 0.05). Conclusion Compared with benazepril alone, benazepril combined with indapamide depressurization effect was significantly improved; heart rate, blood glucose, total cholesterol and other biochemical indicators had no significant effect; and the incidence of adverse reactions is low, safe and reliable .